Frebourg T, Lerebours G, Delpech B, Benhamou D, Bertrand P, Maingonnat C, Boutin C, Nouvet G
Cancer. 1987 Jun 15;59(12):2104-7. doi: 10.1002/1097-0142(19870615)59:12<2104::aid-cncr2820591224>3.0.co;2-i.
The diagnostic value of hyaluronate concentration in effusions of malignant mesothelioma has been extensively reported but no information is available about serum hyaluronate in patients with this cancer. Using a new enzymoimmunologic assay based on hyaluronate-hyaluronectin interaction, serum levels of hyaluronate were measured in 16 patients with malignant pleural mesothelioma, 50 patients with other pleural effusions, and 94 healthy blood donors. The mean serum hyaluronate level in patients with mesothelioma (mean, 750 micrograms/l; range, 29 to 5833 micrograms/l) was significantly higher than in patients with other pleural effusions (mean, 56 micrograms/l; range, 4 to 137 micrograms/l) and than in blood donors (mean, 24 micrograms/l; range, 0 to 94 micrograms/l). Comparison of serum hyaluronate values observed in mesotheliomas with the clinical course of the disease suggests that serum hyaluronate might increase only at an advanced stage of the cancer. Therefore, serum hyaluronate determination has probably no clinical value for early detection of malignant mesothelioma, but might be useful to evaluate the clinical course of this malignancy.
透明质酸盐浓度在恶性间皮瘤积液中的诊断价值已有大量报道，但关于该癌症患者血清透明质酸盐的信息却未见报道。采用一种基于透明质酸盐-透明质粘连蛋白相互作用的新型酶免疫测定法，对16例恶性胸膜间皮瘤患者、50例其他胸腔积液患者和94名健康献血者的血清透明质酸盐水平进行了检测。间皮瘤患者的血清透明质酸盐平均水平（平均为750微克/升；范围为29至5833微克/升）显著高于其他胸腔积液患者（平均为56微克/升；范围为4至137微克/升）和献血者（平均为24微克/升；范围为0至94微克/升）。将间皮瘤患者观察到的血清透明质酸盐值与疾病临床进程进行比较表明，血清透明质酸盐可能仅在癌症晚期升高。因此，血清透明质酸盐测定对恶性间皮瘤的早期检测可能没有临床价值，但可能有助于评估这种恶性肿瘤的临床进程。
